Over the past three years, thousands of studies on Long COVID have been published. But very few have led to tangible benefits for the millions of people living with this often-debilitating condition.
It’s too soon to make any concrete promises, but researchers expect that to change. “In the short history of studying this disease, this is probably the most hopeful moment we’ve ever had,” researcher Christoph Thaiss told me for a new story.
Within the past couple months, two large studies—one co-authored by Thaiss—have found potential biomarkers that could make it easier to diagnose Long COVID. That’s big on its own, since lots of people are misdiagnosed or entirely missed by physicians who don’t have much experience in Long COVID. But it also opens the doors to potential treatments, because understanding what causes a condition makes it that much easier to get it under control.
If you want to optimize your workouts to get the widest range of benefits, you might want to try exercising in the morning. (Originally published in 2019.)
Novo Nordisk, the Denmark-based maker of blockbuster drugs Ozempic and Wegovy, is a very big fish in very small pond. As Stephen Wilmot reports in the Wall Street Journal, Novo's shares are overwhelming the stock index of Danish companies, creating a peculiar a set of problems for Danish investors.
